LakeShore Total Debt To Capitalization from 2010 to 2024

LSBPW Stock   0.04  0.00  0.00%   
LakeShore Biopharma Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2024. During the period from 2010 to 2024, LakeShore Biopharma Total Debt To Capitalization regression line of quarterly data had mean square error of  0.13 and geometric mean of  0.01. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.41638744
Current Value
0.44
Quarterly Volatility
0.35153769
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.9 M, Interest Expense of 29.6 M or Selling General Administrative of 130.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 0.0 or Days Sales Outstanding of 304. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Check out the analysis of LakeShore Biopharma Correlation against competitors.

Latest LakeShore Biopharma's Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of LakeShore Biopharma Co, over the last few years. It is LakeShore Biopharma's Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Pretty Stable
   Total Debt To Capitalization   
       Timeline  

LakeShore Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation3,868
Mean Deviation0.16
Median(0)
Standard Deviation0.35
Sample Variance0.12
Range1.5371
R-Value0.15
Mean Square Error0.13
R-Squared0.02
Significance0.60
Slope0.01
Total Sum of Squares1.73

LakeShore Total Debt To Capitalization History

2024 0.44
2023 0.42
2022 0.4
2021 -1.1

About LakeShore Biopharma Financial Statements

LakeShore Biopharma investors use historical fundamental indicators, such as LakeShore Biopharma's Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LakeShore Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.42  0.44 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LakeShore Stock Analysis

When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.